Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...
Targeted Oncology16h
FDA Accepts BLA for RP1 With Nivolumab in Advanced Melanoma
The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...
FDA accepts Replimune's advanced melanoma therapy BLA
Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...
Replimune stock soars on FDA priority review for melanoma treatment
Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...
Healio10d
Adjuvant nivolumab improves DFS in high-risk head and neck cancer
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...
Targeted Oncology11d
Post-Operative Nivolumab Significantly Improves DFS in Head and Neck Cancer
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
The American Journal of Managed Care20d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...
Oncology Nurse Advisor8d
Nivolumab Plus Ipilimumab Bests Chemo in MSI-H, dMMR Colorectal Cancer
In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...
oncnursingnews5dOpinion
Opinion: Subcutaneous Nivolumab Offers an Effective Alternative to Intravenous Administration
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
Cure Today13d
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...